Suppr超能文献

药代动力学与最低抑菌浓度的非线性相互作用对痰菌杀灭率的影响,作为结核病杀菌效果的一个指标

Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.

作者信息

Chigutsa Emmanuel, Pasipanodya Jotam G, Visser Marianne E, van Helden Paul D, Smith Peter J, Sirgel Frederick A, Gumbo Tawanda, McIlleron Helen

机构信息

Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.

Office of Global Health, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

出版信息

Antimicrob Agents Chemother. 2015 Jan;59(1):38-45. doi: 10.1128/AAC.03931-14. Epub 2014 Oct 13.

Abstract

The relationships between antituberculosis drug exposure and treatment effects on humans receiving multidrug therapy are complex and nonlinear. In patients on treatment, an analysis of the rate of decline in the sputum bacillary burden reveals two slopes. The first is the α-slope, which is thought to reflect bactericidal effect, followed by a β-slope, which is thought to reflect sterilizing activity. We sought to characterize the effects of standard first-line treatment on sterilizing activity. Fifty-four patients receiving combination therapy for pulmonary tuberculosis in a clinical trial had drug concentrations measured and Mycobacterium tuberculosis isolates available for MIC identification. Sputum sample cultures were performed at baseline and weekly for 8 weeks. A time-to-event model based on the days to positivity in the liquid cultures was used to estimate the β-slope. The pharmacokinetic parameters of rifampin, isoniazid, ethambutol, and pyrazinamide were determined for each patient. Multivariate adaptive regression splines analyses, which simultaneously perform linear and nonlinear analyses, were used to identify the relationships between the predictors and the β-slope. The potential predictors examined included HIV status, lung cavitation, 24-h area under the concentration-time curve (AUC), peak drug concentration (Cmax), AUC/MIC ratio, Cmax/MIC ratio, and the time that that concentration persisted above MIC. A rifampin Cmax of >8.2 mg/liter and a pyrazinamide AUC/MIC of >11.3 were key predictors of the β-slope and interacted positively to increase the β-slope. In patients with a rifampin AUC of <35.4 mg · h/liter, an increase in the pyrazinamide AUC/MIC and/or ethambutol Cmax/MIC increased the β-slope, while increasing isoniazid Cmax decreased it, suggesting isoniazid antagonism. Antibiotic concentrations and MICs interact in a nonlinear fashion as the main drivers of a sterilizing effect. The results suggest that faster speeds of sterilizing effect might be achieved by omitting isoniazid and by increasing rifampin, pyrazinamide, and ethambutol exposures. However, isoniazid and ethambutol exposures may only be of importance when rifampin exposure is low. These findings need confirmation in larger studies. (This study has been registered at controlled-trials.com under registration no. ISRCTN80852505.).

摘要

抗结核药物暴露与接受多药治疗的人类治疗效果之间的关系复杂且呈非线性。在接受治疗的患者中,对痰菌负荷下降速率的分析显示出两个斜率。第一个是α斜率,被认为反映杀菌效果,随后是β斜率,被认为反映灭菌活性。我们试图描述标准一线治疗对灭菌活性的影响。在一项临床试验中,对54例接受肺结核联合治疗的患者测量了药物浓度,并获得了可用于最低抑菌浓度(MIC)鉴定的结核分枝杆菌分离株。在基线时以及每周进行一次痰样本培养,持续8周。使用基于液体培养中阳性天数的事件发生时间模型来估计β斜率。确定了每位患者利福平、异烟肼、乙胺丁醇和吡嗪酰胺的药代动力学参数。使用同时进行线性和非线性分析的多变量自适应回归样条分析来确定预测因子与β斜率之间的关系。所检查的潜在预测因子包括HIV状态、肺空洞、浓度-时间曲线下24小时面积(AUC)、药物峰浓度(Cmax)、AUC/MIC比值、Cmax/MIC比值以及浓度持续高于MIC的时间。利福平Cmax>8.2毫克/升和吡嗪酰胺AUC/MIC>11.3是β斜率的关键预测因子,且呈正相互作用以增加β斜率。在利福平AUC<35.4毫克·小时/升的患者中,吡嗪酰胺AUC/MIC和/或乙胺丁醇Cmax/MIC的增加会增加β斜率,而异烟肼Cmax的增加则会降低β斜率,提示异烟肼存在拮抗作用。抗生素浓度和MIC以非线性方式相互作用,作为灭菌效果的主要驱动因素。结果表明,通过省略异烟肼并增加利福平、吡嗪酰胺和乙胺丁醇的暴露量,可能实现更快的灭菌效果。然而,异烟肼和乙胺丁醇的暴露量可能仅在利福平暴露量较低时才重要。这些发现需要在更大规模的研究中得到证实。(本研究已在controlled-trials.com上注册,注册号为ISRCTN80852505。)

相似文献

1
2
Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis.
Clin Infect Dis. 2017 May 15;64(10):1350-1359. doi: 10.1093/cid/cix158.
3
Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines.
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2171-9. doi: 10.1128/AAC.02600-15. Print 2016 Apr.
4
Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis.
Antimicrob Agents Chemother. 2017 Jul 25;61(8). doi: 10.1128/AAC.00490-17. Print 2017 Aug.
5
Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients.
Antimicrob Agents Chemother. 2013 Jul;57(7):3208-13. doi: 10.1128/AAC.02599-12. Epub 2013 Apr 29.
7
Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.
Eur J Clin Pharmacol. 2016 Aug;72(8):905-16. doi: 10.1007/s00228-016-2083-4. Epub 2016 Jun 15.
8
Rifampicin and Isoniazid Maximal Concentrations are Below Efficacy-associated Thresholds in the Majority of Patients: Time to Increase the Doses?
Int J Antimicrob Agents. 2021 Mar;57(3):106297. doi: 10.1016/j.ijantimicag.2021.106297. Epub 2021 Feb 1.
10
Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.
Antimicrob Agents Chemother. 2006 Apr;50(4):1170-7. doi: 10.1128/AAC.50.4.1170-1177.2006.

引用本文的文献

2
Tuberculosis treatment failure: what are the risk factors? A comprehensive literature review.
Multidiscip Respir Med. 2025 Jul 4;20(1):1030. doi: 10.5826/mrm.2025.1030.
4
A pharmacometric multistate model for predicting long-term treatment outcomes of patients with pulmonary TB.
J Antimicrob Chemother. 2024 Oct 1;79(10):2561-2569. doi: 10.1093/jac/dkae256.
5
The impact of alcohol and illicit substance use on the pharmacokinetics of first-line TB drugs.
J Antimicrob Chemother. 2024 Aug 1;79(8):2022-2030. doi: 10.1093/jac/dkae206.
7
Pharmacokinetic Considerations for Optimizing Inhaled Spray-Dried Pyrazinoic Acid Formulations.
Mol Pharm. 2023 Sep 4;20(9):4491-4504. doi: 10.1021/acs.molpharmaceut.3c00199. Epub 2023 Aug 17.
9
A physiologically-based pharmacokinetic model for tuberculosis drug disposition at extrapulmonary sites.
CPT Pharmacometrics Syst Pharmacol. 2023 Sep;12(9):1274-1284. doi: 10.1002/psp4.13008. Epub 2023 Jul 16.

本文引用的文献

1
The pyrazinamide susceptibility breakpoint above which combination therapy fails.
J Antimicrob Chemother. 2014 Sep;69(9):2420-5. doi: 10.1093/jac/dku136. Epub 2014 May 12.
2
Serum drug concentrations predictive of pulmonary tuberculosis outcomes.
J Infect Dis. 2013 Nov 1;208(9):1464-73. doi: 10.1093/infdis/jit352. Epub 2013 Jul 29.
5
Predictors of anemia after bariatric surgery using multivariate adaptive regression splines.
Hepatogastroenterology. 2012 Jul-Aug;59(117):1378-80. doi: 10.5754/hge10155.
8
Population pharmacokinetics of ethambutol in South African tuberculosis patients.
Antimicrob Agents Chemother. 2011 Sep;55(9):4230-7. doi: 10.1128/AAC.00274-11. Epub 2011 Jun 20.
9
Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients.
Br J Clin Pharmacol. 2011 Jul;72(1):51-62. doi: 10.1111/j.1365-2125.2011.03940.x.
10
The effect of vitamin A and zinc supplementation on treatment outcomes in pulmonary tuberculosis: a randomized controlled trial.
Am J Clin Nutr. 2011 Jan;93(1):93-100. doi: 10.3945/ajcn.110.001784. Epub 2010 Nov 10.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验